A synthetic biology company using rational design to create novel drugs for therapeutic areas with high unmet needs, General Biologics Inc is described as engineering company initially structured around using modern tools of molecular biology, protein biochemistry, and synthetic biology to design, build, test, and ultimately sell, rationally designed proteins for therapeutic use. With the founders of the firm bringing to the table decades of experience in academia, small industrial biotech companies along with large pharmaceutical firms, General Biologics own rights to proprietary technology for binding therapeutic proteins to the surface of red blood cells in a manner that confers superior properties to the therapeutic proteins and the firm has applied for the application for the required permit to begin recombinant DNA work.
